-
Toward Durable Disease Control in EGFR-Mutant (mt) NSCLC: Interpreting the Survival Signals from FLAURA2 and MARIPOSA
Add ILCN as a preferred sourceWhile the FLAURA2 and MARIPOSA trials represent a defining step toward durable disease control in EGFR mt (+) NSCLC, Drs. Ilit Turgeman and Pasi A. Jänne emphasize that further advances will depend on understanding what persists after an initial response.
More Recent News
-
LIBRETTO-432 Trial Results Support Comprehensive Biomarker Testing in Early-Stage Disease
Dr. Jonathan W. Goldman said that findings from the LIBRETTO-432 trial support adjuvant selpercatinib as a new standard of care for patients with early-stage RET fusion-positive NSCLC.
-
Knowing Before We Can Act: The Value of MRD Testing From a Patient’s Perspective
While MRD testing does not eliminate the uncertainty of recurrence, Jan Pezarro explains how advanced molecular testing provides invaluable clarity for patients.